<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595644</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC-LC001</org_study_id>
    <nct_id>NCT03595644</nct_id>
  </id_info>
  <brief_title>Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer</brief_title>
  <official_title>Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body&#xD;
      Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer&#xD;
      (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving&#xD;
      treatment with a targeted agent such as gefitinib, erlotinib and icotinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2017</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival: From the first treatment to the date of first documentation of disease progression, or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 year</time_frame>
    <description>Overall survival: From the first administration to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT plus TKI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT+TKI</intervention_name>
    <description>Received SBRT after three months after EGFR-TKI treatment</description>
    <arm_group_label>SBRT plus TKI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI</intervention_name>
    <description>Received EGFR-TKI treatment</description>
    <arm_group_label>TKI treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).&#xD;
&#xD;
          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved&#xD;
             stable disease or a partial response.&#xD;
&#xD;
          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR&#xD;
             mutant-positive for 3 months and achieved stable disease, partial response or&#xD;
             completely response.&#xD;
&#xD;
          4. Age 18 to 75 years old.&#xD;
&#xD;
          5. Patients must have measurable disease at baseline.&#xD;
&#xD;
          6. The amount of metastatic focus &lt;5.&#xD;
&#xD;
          7. ECOG score 0-2&#xD;
&#xD;
          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.&#xD;
&#xD;
          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)&#xD;
&#xD;
         10. Patients must provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who previously received radiotherapy to the primary site.&#xD;
&#xD;
          2. Patient can't tolerate radiotherapy or targeted therapy;&#xD;
&#xD;
          3. Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li Zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11.</citation>
    <PMID>28973074</PMID>
  </reference>
  <reference>
    <citation>Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.</citation>
    <PMID>27789196</PMID>
  </reference>
  <reference>
    <citation>de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014 Feb;25(2):467-71. doi: 10.1093/annonc/mdt537. Epub 2013 Dec 18.</citation>
    <PMID>24355488</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

